What does myostatin do?

It restrains skeletal muscle growth by signalling through activin type II receptors, suppressing protein synthesis and promoting degradation.

Why block the receptor rather than myostatin itself?

Several ligands converge on the same receptor, so blocking it catches more of the signalling than blocking one ligand.

Does it only preserve muscle?

Nunn 2024 reports it also enhances fat loss during GLP-1 agonism — plausibly because preserved muscle maintains resting energy expenditure.

GLP-1 & Incretin Science

Blocking the Brake on Muscle Growth

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Myostatin and related ligands restrain skeletal muscle growth by signalling through activin type II receptors. Blocking those receptors removes the restraint. Nunn and colleagues reported in Molecular Metabolism in 2024 that this preserves muscle mass and enhances fat loss during GLP-1 receptor agonism.

Key facts

Pathway: Myostatin / activin signalling
Target: Activin type II receptors
Normal role: Restrains muscle growth
Effect of blockade: Muscle preserved or increased
Additional reported effect: Enhanced fat loss
Mechanism paper: Nunn 2024 (PMID 38218536)

Why a brake on muscle growth exists

Muscle is metabolically expensive to build and maintain. An organism that built muscle without limit would waste energy it might need elsewhere, so growth is actively restrained. Myostatin is the principal restraining signal, and animals lacking functional myostatin are markedly more muscular — which is what established the pathway's role.

How the signal is delivered

Myostatin and related ligands bind activin type II receptors on muscle cells, initiating signalling that suppresses protein synthesis and promotes degradation. Blocking the receptor rather than the ligand catches several ligands converging on the same point, which is why the receptor is the more effective intervention target.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

The finding that made this interesting for obesity

Nunn and colleagues titled their 2024 Molecular Metabolism paper to state it directly: antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism. The second half is the surprise — the intervention did not merely protect muscle while fat loss continued unchanged, it reportedly increased fat loss.

Why enhanced fat loss is plausible rather than convenient

Muscle is metabolically active tissue. Preserving or increasing it maintains resting energy expenditure that would otherwise fall as mass is lost. A larger metabolically active compartment burning more energy is a coherent route from muscle preservation to greater fat loss, and it makes the combination more than the sum of two separate effects.

Why the combination logic is compelling

Incretin agonism reduces intake and produces loss across compartments. Activin receptor blockade shifts which compartment the loss comes from. The two act on different mechanisms with no obvious overlap, which is the profile that makes a combination worth testing rather than redundant.

What remains unestablished

Whether any of this translates to human functional outcomes, and what blocking a growth-restraining pathway does over years. Preclinical mechanism and Phase 2 body composition data are not the same as demonstrated clinical benefit, and no compound in this class holds an authorisation for obesity anywhere.

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

What does myostatin do?: It restrains skeletal muscle growth by signalling through activin type II receptors, suppressing protein synthesis and promoting degradation.
Why block the receptor rather than myostatin itself?: Several ligands converge on the same receptor, so blocking it catches more of the signalling than blocking one ligand.
Does it only preserve muscle?: Nunn 2024 reports it also enhances fat loss during GLP-1 agonism — plausibly because preserved muscle maintains resting energy expenditure.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum